These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34482090)

  • 41. The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project.
    Laufs U; Catapano AL; De Caterina R; Schiele F; Sionis A; Zaman A; Jukema JW
    Vascul Pharmacol; 2023 Feb; 148():107141. PubMed ID: 36626974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New guidelines on dyslipidemia management: Comparison of French (HAS) and European (ESC/EAS) guidelines].
    Farnier M
    Presse Med; 2018 Sep; 47(9):769-774. PubMed ID: 30274915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
    Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Nabavi SM; Lavie CJ; Banach M;
    Prog Cardiovasc Dis; 2021; 67():65-74. PubMed ID: 33383060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.
    Jones PH; Nair R; Thakker KM
    J Am Heart Assoc; 2012 Dec; 1(6):e001800. PubMed ID: 23316314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
    Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study.
    Banach M; Lewek J; Pol K; Rabczenko D; Balanescu SM; Blaha V; Ceska R; Jankowski P; Surma S; Kolovou G; Liberopoulos E; Mitu F; Mitu M; Naji FH; Paragh G; Popławska M; Vrablik M; Pella D
    Front Cardiovasc Med; 2023; 10():1206551. PubMed ID: 37404744
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.
    Barkas F; Liberopoulos EN; Kostapanos MS; Liamis G; Tziallas D; Elisaf M
    Angiology; 2015 Apr; 66(4):346-53. PubMed ID: 24830420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of dyslipidaemia in patients treated with lipid-modifying drugs in the Netherlands. Part of the dyslipidaemia international survey.
    Strang AC; Kaasjager HA; Basart DC; Stroes ES
    Neth J Med; 2010 Apr; 68(4):168-74. PubMed ID: 20421658
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre: analysis of the impact of new ESC guidance on LDL-C target achievement.
    McCaughey C; Ranganathan D; Kerins M; Murphy G; Murphy R
    Ir J Med Sci; 2022 Dec; 191(6):2569-2577. PubMed ID: 35031936
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS).
    Raal FJ; Blom DJ; Naidoo S; Bramlage P; Brudi P
    Cardiovasc J Afr; 2013 Sep; 24(8):330-8. PubMed ID: 24240385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II.
    Eber B; Lautsch D; Fauer C; Drexel H; Pfeiffer KP; Traindl O; Pichler M
    Curr Med Res Opin; 2012 Sep; 28(9):1447-54. PubMed ID: 22856551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].
    Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of application of the new 2019 European Society of Cardiology/ European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias in daily clinical practice - one center study.
    Cecha P; Chromik A; Piotrowska I; Zabojszcz M; Dolecka-Ślusarczyk M; Siudak Z
    Folia Med Cracov; 2021 Sep; 61(3):43-54. PubMed ID: 34882663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [ECS guidelines 2016 - dyslipidaemias].
    Sinning D; Landmesser U
    Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study.
    Ray KK; Haq I; Bilitou A; Manu MC; Burden A; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrières J; Laufs U; Mostaza JM; Nanchen D; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL;
    Lancet Reg Health Eur; 2023 Jun; 29():100624. PubMed ID: 37090089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.